Literature DB >> 10030773

Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies.

G Micali1, K Linthicum, N Han, D P West.   

Abstract

Erythema multiforme major (EMM; Stevens-Johnson syndrome) is a cutaneous disorder associated with a wide variety of factors including ingestion of drugs such as phenytoin and exposure to intracranial radiation therapy. Based on observations of a 47-year-old black man with brain metastases who developed EMM after combined phenytoin and radiation therapy, we conducted a MEDLINE literature search for articles on similar cases from 1966 to the present. Twenty cases were identified that support the hypothesis that EMM is associated with combined phenytoin and radiation therapy. The reaction, or its severity, has no relationship to the phenytoin or radiation therapy dosage, or to the histologic type of brain tumor. Also, EMM has no apparent age or gender predisposition in association with phenytoin-radiation therapy. Thus this is a clinical phenomenon that occurs with unusual frequency in patients with brain tumor who undergo radiation therapy while taking phenytoin. Phenytoin and other anticonvulsants such as phenobarbital and carbamazepine induce cytochrome P450 3A and produce oxidative reactive intermediates that may be implicated in hypersensitivity reactions such as EMM. Both carbamazepine and barbiturates have shown cross-sensitivity with phenytoin; furthermore, a case of EMM in a patient receiving carbamazepine and whole brain radiation therapy has been reported. As carbamazepine, valproate, and barbiturates have been associated with EMM, gabapentin may be considered as alternative anticonvulsant therapy when appropriate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10030773     DOI: 10.1592/phco.19.3.223.30917

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  13 in total

1.  Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy.

Authors:  M Maschio; L Dinapoli; A Vidiri; Paola Muti
Journal:  J Neurol       Date:  2010-07-08       Impact factor: 4.849

2.  EMPACT syndrome: limited evidence despite a high-risk cohort.

Authors:  Andrew J Bishop; Maria Chang; Mario E Lacouture; Christopher A Barker
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

3.  Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life.

Authors:  Marta Maschio; Loredana Dinapoli; Francesca Sperati; Andrea Pace; Alessandra Fabi; Antonello Vidiri; Paola Muti
Journal:  J Neurooncol       Date:  2010-11-25       Impact factor: 4.130

4.  Multifocal Stevens-Johnson syndrome after concurrent phenytoin and cranial and thoracic radiation treatment, a case report.

Authors:  Abdullah O Kandil; Tomas Dvorak; John Mignano; Julian K Wu; Jay-Jiguang Zhu
Journal:  Radiat Oncol       Date:  2010-06-04       Impact factor: 3.481

Review 5.  Epilepsy and brain tumors.

Authors:  Dario J Englot; Edward F Chang; Charles J Vecht
Journal:  Handb Clin Neurol       Date:  2016

6.  Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider.

Authors:  David Aguiar; Roberto Pazo; Ignacio Durán; Josefa Terrasa; Antonio Arrivi; Herminio Manzano; Javier Martín; Julio Rifá
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

Review 7.  Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.

Authors:  Terri S Armstrong; Robin Grant; Mark R Gilbert; Jong Woo Lee; Andrew D Norden
Journal:  Neuro Oncol       Date:  2015-11-02       Impact factor: 12.300

8.  Stevens Johnson Syndrome in a patient undergoing gynaecological brachytherapy: An association or an incident?

Authors:  Miguel Reis Ferreira; Ana Amado; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2011-04-08

9.  12-Tungstophospho-ric acid-1,1'-methyl-enebis(imidazolidine-2,4-dione)-imidazolidine-2,4-dione-water (2/1/4/21.5).

Authors:  Mohammad Hasan Alizadeh; Irandokht Mohammadi Zonoz
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-06-23

10.  Update in palliative management of hormone refractory cancer of prostate.

Authors:  Pratipal Singh; Aneesh Srivastava
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.